FDA expands gluten labeling to protect celiac patients—at modest cost to food makers
H.R. 9988 — FASTER Act of 2026 · Filed by Anna Luna (R-FL) · 13 cosponsors · Introduced Jul 30, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill adds barley, rye, and oats to the FDA's list of major food allergens (alongside wheat), requiring food manufacturers to clearly label these ingredients on packaging. The FDA has one year to update its compliance guidance, and the new labeling rules take effect one year after enactment. The bill also directs the Department of Health and Human Services to study celiac disease prevalence, diagnostics, and potential treatments.
Why we flagged it
The bill's core function is to expand FDA allergen labeling requirements to protect consumers with celiac disease and gluten sensitivity. The celiac research directive is a supporting public-health component, not a separate purpose.
What the text implies
- Food manufacturers will incur compliance costs (reformulation testing, label redesign, supply-chain audits) that may be passed to consumers through modest price increases, disproportionately affecting budget-conscious households.
- The one-year phase-in may create temporary market confusion if some products are labeled under old rules while others comply with new rules, potentially misleading consumers during the transition.
The full analysis lists 4 implications of this text.
Who stands to gain
Food manufacturers (compliance consulting, testing, labeling services); Diagnostic and pharmaceutical companies (if celiac research accelerates product development); Gluten-free food producers (potential market expansion as awareness increases)